Why Is HIMS & HERS HEALTH I A (HIMS) Stock Down Today?

HIMS stock fell 6.05% to $29.83 on August 27, 2026, driven by a major Federal Trade Commission lawsuit and growing investor concerns over corporate compliance. The FTC filed a lawsuit against the company on July 29, 2026, alleging issues with privacy and billing practices. This followed additional legal scrutiny from multiple law firms investigating potential securities law violations. The stock’s decline was also amplified by a recent regulatory action from Visa, which placed Hims & Hers into its Acquirer Monitoring Program due to a spike in billing disputes, adding financial pressure amid an already challenging operating environment.

What Happened

The stock’s sharp drop came amid a surge in legal and regulatory actions against Hims & Hers Health. The FTC lawsuit, announced in late July, alleged the company violated consumer protection laws related to privacy and billing. On August 26, PR Newswire reported that Hagens Berman was investigating corporate compliance and investor implications, while multiple law firms including Kaplan Fox & Kilsheimer and Glancy Prongay Wolke & Rotter announced ongoing securities fraud investigations. Yahoo Finance highlighted Visa’s penalty action as a compounding factor, noting increased costs and margin pressures. Hims & Hers management also announced a virtual meeting with KeyBanc, but the news failed to offset the negative momentum.

What The Data Shows

The stock has traded in a 52-week range of $13.74 to $65.30 and has a market cap of $7.3 billion. Despite a 28.0% year-to-date revenue increase, the company remains unprofitable with a trailing twelve-month net margin of -5.5% and an EPS of -0.62. Over the last 8 sessions, the stock rose 6.0% from $28.61 to $30.34, but this recent rally failed to hold. Options activity showed a heavy skew toward puts, with $7.1 million in put premiums versus $10,000 in call premiums, and the largest single options print reaching $2.9 million. Insider transactions over the past 90 days show 11 sales totaling $7.2 million versus 1 buy totaling $1.2 million, with the most recent filing on August 20.

What To Watch

The company is scheduled to meet with KeyBanc, and investors will be watching for any updates on corporate strategy or legal defenses. Broader coverage from analysts remains mixed, with Truist Securities maintaining a Hold rating and Barclays an Overweight rating, though both have adjusted price targets.